Comparative Study of 3% Hypertonic Saline Nebulisation Versus 0.9% Normal Saline Nebulisation for Treating Acute BronchiolitisCorrespondence Address :
Dr. Tanveer Bashir,
Senior Resident, Fernandez Hospital, Hyderguda-500048, Hyderabad, Telangana, India.
Introduction: Bronchiolitis is commonly noticed condition in children, especially in infants and characterised by inflammation of bronchioles. Inspite of this common occurrence the evidence for the treatment options is limited.
Aim: To compare the effect of 3% Hypertonic Saline (HS) nebulisation with 0.9% Normal Saline (NS) nebulisation for treating acute bronchiolitis in moderately ill hospitalised infants and children (<18 months) on Length Of Hospital Stay (LOS) and improvement in clinical severity score.
Materials and Methods: This is a randomised controlled trial, done in a tertiary care paediatric hospital over a period of one year from April 2014 to March 2015. Out of 189 children randomised, 96 patients and 93 patients received HS nebulisation and NS nebulisation respectively. Treating doctors and patients were blinded to intervention and outcome.
Results: Reduction in clinical severity score in 3% HS nebulisation group was 2.26 (0.684) and in 0.9% NS nebulisation group was 1.23 (0.492), with statistically significant p<0.001. LOS in 3% HS nebulisation group was 1.45 (0.540) days and in 0.9% NS nebulisation group was 2.35 (0.619) days with mean difference of 0.91 (0.084) day with statistically significant p<0.001.
Conclusion: This study demonstrates that 3% HS nebulisation is safe and effective treatment for infants up to the age of 18 months hospitalised with acute bronchiolitis and decreases hospital stay by about one day.
Bronchiolitis, Nebulisation, Respiratory tract infection
Tanveer Bashir, Kallem Venkat Reddy, Kaiser Ahmed, Saima Shafi. COMPARATIVE STUDY OF 3% HYPERTONIC SALINE NEBULISATION VERSUS 0.9% NORMAL SALINE NEBULISATION FOR TREATING ACUTE BRONCHIOLITIS. Journal of Clinical and Diagnostic Research [serial online] 2018 June [cited: 2018 Jun 23 ]; 12:SC05-SC08. Available from
Date of Submission: Nov 14, 2017
Date of Peer Review: Feb 07, 2018
Date of Acceptance: Mar 19, 2018
Date of Publishing: Jun 01, 2018
FINANCIAL OR OTHER COMPETING INTERESTS: None.
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2016: 132.37
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase & EMbiology
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)